Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Buy
70
CLBT Quote, Financials, Valuation and Earnings
Last price:
$19.22
Seasonality move
:
10.65%
Day range:
$18.60 - $19.28
52-week range:
$13.10 - $26.30
Dividend yield:
0%
P/E ratio:
62.80x
P/S ratio:
10.49x
P/B ratio:
11.50x
Volume:
1.2M
Avg. volume:
1.4M
1-year change:
-9.77%
Market cap:
$4.7B
Revenue:
$401.2M
EPS (TTM):
$0.31
Analysts' Opinion
-
Consensus RatingCellebrite DI Ltd. has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $24.71, Cellebrite DI Ltd. has an estimated upside of 28.65% from its current price of $19.21.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $23.00 representing 100% downside risk from its current price of $19.21.
Fair Value
-
According to the consensus of 6 analysts, Cellebrite DI Ltd. has 28.65% upside to fair value with a price target of $24.71 per share.
CLBT vs. S&P 500
-
Over the past 5 trading days, Cellebrite DI Ltd. has overperformed the S&P 500 by 1.97% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Cellebrite DI Ltd. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Cellebrite DI Ltd. has grown year-over-year revenues for 13 quarters straight. In the most recent quarter Cellebrite DI Ltd. reported revenues of $126M.
Earnings Growth
-
Cellebrite DI Ltd. has grown year-over-year earnings for 4 quarters straight. In the most recent quarter Cellebrite DI Ltd. reported earnings per share of $0.08.
Enterprise value:
4.2B
EV / Invested capital:
--
Price / LTM sales:
10.49x
EV / EBIT:
65.88x
EV / Revenue:
9.19x
PEG ratio (5yr expected):
-0.55x
EV / Free cash flow:
30.13x
Price / Operating cash flow:
34.36x
Enterprise value / EBITDA:
56.43x
Gross Profit (TTM):
$382.8M
Return On Assets:
10.44%
Net Income Margin (TTM):
16.74%
Return On Equity:
20.59%
Return On Invested Capital:
19.76%
Operating Margin:
15.2%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $306.1M | $385.2M | $455.9M | $106.9M | $126M | |
| Gross Profit | $255.7M | $325.3M | $382.8M | $91.4M | $105.7M | |
| Operating Income | $28M | $56.5M | $63.6M | $19.7M | $19.2M | |
| EBITDA | $38M | $66.9M | $74.3M | $22.3M | $21.9M | |
| Diluted EPS | -$0.32 | -$1.55 | $0.31 | -$0.99 | $0.08 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $271.3M | $262.5M | $369M | $494.9M | $668.4M | |
| Total Assets | $315.1M | $352.5M | $476.9M | $629.2M | $834.3M | |
| Current Liabilities | $403.7M | $189.8M | $226.8M | $272.9M | $316.9M | |
| Total Liabilities | $445.1M | $293M | $439M | $330.9M | $386.6M | |
| Total Equity | -$130M | $59.5M | $37.9M | $298.3M | $447.7M | |
| Total Debt | -- | -- | $7.3M | $7.8M | $17.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $94M | $110M | $152.7M | $41.7M | $33.3M | |
| Cash From Investing | -$63.1M | -$130.4M | -$38.1M | -$18.7M | $63.8M | |
| Cash From Financing | $19.2M | $18.5M | $29.4M | $5.5M | $5.3M | |
| Free Cash Flow | $87.8M | $98.8M | $139.1M | $39.8M | $30M | |
CLBT
Sector
Market Cap
$4.7B
$52.2M
Price % of 52-Week High
73.04%
58.64%
Dividend Yield
0%
0%
Shareholder Yield
-0.69%
--
1-Year Price Total Return
-9.77%
-11.85%
Beta (5-Year)
--
0.667
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$18.59
200-day SMA
Buy
Level
$17.24
Bollinger Bands (100)
Buy
Level
15.59 - 18.73
Chaikin Money Flow
Buy
Level
38.8M
20-day SMA
Buy
Level
$17.95
Relative Strength Index (RSI14)
Buy
Level
62.29
ADX Line
Buy
Level
18.56
Williams %R
Sell
Level
-3.4314
50-day SMA
Buy
Level
$17.77
MACD (12, 26)
Buy
Level
0.36
25-day Aroon Oscillator
Buy
Level
76
On Balance Volume
Neutral
Level
75.4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (9.5718)
Sell
CA Score
(Annual)
Level (-0.7157)
Buy
Beneish M-Score
(Annual)
Level (-5.223)
Buy
Momentum Score
Level (5)
Sell
Ohlson Score
Level (2.4689)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (8)
Sell
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Cellebrite DI Ltd. engages in the provision of digital investigative solutions for the public and private sectors, empowering organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. Its services include training and advisory, value realization, advanced services, and technical customer support. The firm also offers software solutions and analytic tools designed to accelerate digital investigations and address the growing complexity of handling crime and security challenges in the digital era. The company was founded on April 13, 1999 and is headquartered in Petach Tikva, Israel.
Stock Forecast FAQ
In the current month, CLBT has received 6 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CLBT average analyst price target in the past 3 months is $24.71.
-
Where Will Cellebrite DI Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Cellebrite DI Ltd. share price will rise to $24.71 per share over the next 12 months.
-
What Do Analysts Say About Cellebrite DI Ltd.?
Analysts are divided on their view about Cellebrite DI Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cellebrite DI Ltd. is a Sell and believe this share price will drop from its current level to $23.00.
-
What Is Cellebrite DI Ltd.'s Price Target?
The price target for Cellebrite DI Ltd. over the next 1-year time period is forecast to be $24.71 according to 6 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CLBT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Cellebrite DI Ltd. is a Buy. 6 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CLBT?
You can purchase shares of Cellebrite DI Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cellebrite DI Ltd. shares.
-
What Is The Cellebrite DI Ltd. Share Price Today?
Cellebrite DI Ltd. was last trading at $19.22 per share. This represents the most recent stock quote for Cellebrite DI Ltd.. Yesterday, Cellebrite DI Ltd. closed at $19.21 per share.
-
How To Buy Cellebrite DI Ltd. Stock Online?
In order to purchase Cellebrite DI Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get CLBT Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CLBT
Sector
P/E ratio
62.80x
23.85x
PEG ratio
-0.55x
0.00x
P/B ratio
11.50x
2.11x
Price / LTM sales
10.49x
1.41x
Growth Metrics
CLBT
Sector
Revenue growth
17.94%
6.61%
Earnings growth
108.06%
10.79%
Revenue (5-year growth)
18.48%
4.95%
Earnings forecast
$0.11
$0.13
Profitability
CLBT
Sector
Profitability FY 2024
$338.6M
$29.8M
Return on invested capital
19.76%
-0.62%
Return on assets
10.44%
-1.32%
Return on equity
20.59%
0.23%
Earnings Date
Last Earnings Date
Nov
12
Next Earnings Date
Feb
19
Estimated Next Earnings Date
Feb
11
Balance Sheet
CLBT
Sector
Total cash
$525.7M
$39.6M
Short term investments
$255.6M
$16.4M
Total assets
$696.6M
$158.9M
Long term debt
$17.8M
$4.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
